^
Association details:
Biomarker:NTRK1 fusion
Cancer:Solid Tumor
Drug Class:Trk inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

100P - Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice

Published date:
09/13/2021
Excerpt:
...small cohort of TRKi-naïve pts, OS was similarly poor in pts with NTRK+ metastatic/LA cancers vs matched NTRK– pts; this contrasts with improved OS in pts with NTRK+ tumours who receive TRKi therapy.